Expression of the GLP-1 receptor in the liver of NAFLD patients is significantly downregulated, and butyrate supplementation enhances the expression of the GLP-1 receptor in the livers of mice with NAFLD by inhibiting HDAC-2, which in turn promotes energy metabolism and inhibits lipid accumulation [178]. Here, HDAC2 is linked to metabolic dysfunction-associated steatotic liver disease.